Optimal duration of chemotherapy in advanced non-small cell lung cancer

Medicine and Dentistry

• Chemotherapy 100%
• Non Small Cell Lung Cancer 100%
• Platinum 100%
• Patient 75%
• Erlotinib 75%
• Treatment Duration 75%
• Combination Therapy 50%
• Disease 50%
• Health Care Cost 50%
• Survival 50%
• Toxicity 50%
• Quality of Life 50%
• Bevacizumab 50%
• Lung Cancer 25%
• Clinical Trial 25%
• Overall Survival 25%
• Relapse 25%
• Gemcitabine 25%
• Docetaxel 25%
• Cisplatin 25%
• Cancer Mortality 25%
• Carboplatin 25%
• Paclitaxel 25%
• Combination Chemotherapy 25%
• Pemetrexed 25%
• Non-Small Cell Lung Cancer 25%
• Effusion 25%
• First-Line Chemotherapy 25%
• Epidermal Growth Factor Receptor Kinase Inhibitor 25%
• Matrix Metalloproteinase Inhibitor 25%
• Bexarotene 25%
• Targeted Therapeutic Agent 25%
• Gefitinib 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Platinum 80%
• Erlotinib 60%
• Diseases 40%
• Survival 40%
• Toxicity 40%
• Bevacizumab 40%
• Lung Cancer 20%
• Relapse 20%
• Gemcitabine 20%
• Docetaxel 20%
• Cisplatin 20%
• Paclitaxel 20%
• Carboplatin 20%
• Cancer Mortality 20%
• Overall Survival 20%
• Pemetrexed 20%
• Epidermal Growth Factor Receptor Kinase Inhibitor 20%
• Bexarotene 20%
• Gefitinib 20%
• Effusion 20%
• Matrix Metalloproteinase Inhibitor 20%